Literature DB >> 11200129

Indications, results, and pitfalls in the surgery of constrictive pericarditis.

R Moosdorf1.   

Abstract

Constrictive pericarditis is a rare disease with an often unclear etiology. There may be a long delay between the onset of the underlying disease and the onset of clinical symptoms, which are fatigue, abdominal swelling, peripheral edema and breathlessness. However, if clinically apparent, these symptoms may progress rapidly and severely disable the affected patient. Diagnosis is achieved by the clinical presentation, echocardiography and/or MRI and right heart catheterization. The standard therapy is an extended pericardiectomy to restore an unlimited inflow and outflow as well as an unrestricted diastolic function of both ventricles. The risks of this procedure are related to dense adhesions between the 2 pericardial layers and severe calcifications especially of the epicardium. Incomplete removal results in persistent diastolic restriction while lacerations of the underlying myocardium may lead to diffuse and extensive bleeding and finally to myocardial dysfunction. Also, the postoperative course may be complicated by persistent low output syndrome or acute ventricular dilatation. However, early surgical intervention in the hands of experienced surgeons offers the best prognosis.

Entities:  

Mesh:

Year:  2000        PMID: 11200129     DOI: 10.1007/pl00001999

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  2 in total

1.  Validation of Waffle procedure for constrictive pericarditis with epicardial thickening.

Authors:  Manabu Shiraishi; Atsushi Yamaguchi; Kenichi Muramatsu; Naoyuki Kimura; Koichi Yuri; Harunobu Matsumoto; Kouichi Adachi; Hideo Adachi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2014-06-13

2.  Severe heart failure due to subacute effusive-constrictive pericarditis in a child.

Authors:  C Suita; I Shiraishi; T Tanaka; K Shuntoh; M Yamagishi; K Hamaoka
Journal:  Pediatr Cardiol       Date:  2005 Jan-Feb       Impact factor: 1.655

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.